Biotech Firm Unveils New Inflammatory Disease, Cancer Therapy

Israeli biotech company Amorphical says it has developed a new mineral-based approach to treating a range of chronic inflammatory diseases and cancers. 

The Nes Ziona-based company, which was founded in 2004, says its new technology involves the production of amorphous calcium carbonate that allows the body to quickly and efficiently absorb essential minerals. 

The therapy also has the unique ability to stimulate healing inside damaged tissue targeted during therapy, the company says, due to the mineral’s unique dissolving properties.  

With inflammatory diseases such as Crohn’s disease, multiple sclerosis and arthritis, Amorphical says the carbonate calcium neutralizes the acidity within the affected tissue, creating a neutral environment that does not allow the inflammation to occur. 

Similarly, according to Amorphical, a reduction of acidity by carbonate calcium inhibits the growth of cancer cells, as they need an acidic environment in order to rapidly reproduce. 

The treatment is suitable for a range of cancers, including breast, prostate and colon, Amorphical says. 

It claims that this is the only technology in the world that can cure a wide range of cancers by creating a healthy environment in which the tumors cannot survive. 

The company also says that its amorphous calcium carbonate therapy has also been highly effective in treating COVID-19 as well as significantly slowing down the aging process and improving quality of life.